What is the AQUAPASS System approved for in Israel?

The AQUAPASS System is approved in Israel for patients experiencing fluid overload, particularly those in nephrology and cardiology.

How does Aquapass's fluid overload therapy work?

Aquapass's technology removes fluid directly from the interstitial space via the skin, without depending on kidney function.

When will Aquapass submit for US FDA clearance?

Aquapass plans to submit for US FDA clearance in the second quarter of 2026.

Home / Health / Aquapass System Transforms Fluid Overload Treatment

Aquapass System Transforms Fluid Overload Treatment

9 Dec

•

Summary

Aquapass received marketing approval in Israel for its fluid overload system.
The system allows fluid removal directly through the skin, independent of kidney function.
US FDA clearance submission is targeted for Q2 2026 after trial completion.

Aquapass System Transforms Fluid Overload Treatment

Aquapass has achieved a pivotal milestone with marketing approval for its AQUAPASS System in Israel, targeting patients suffering from fluid overload. This regulatory clearance enables the company to begin commercial deployment in Israeli medical centers, a crucial step from development to clinical application. The system is designed for diverse patient groups, including those with acute and chronic conditions across nephrology and cardiology.

CEO Noam Josephy highlighted this approval as a transition to the commercial phase, emphasizing the company's mission to aid critically ill patients. The AQUAPASS technology distinguishes itself by enabling direct fluid removal through the skin, bypassing the need for kidney function. This innovation holds promise for transforming fluid overload management, particularly for individuals with heart failure and kidney disease.